Strategic appointments at Inventiva to strengthen R&D and regulatory affairs

Biopharmaceutical company Inventiva has announced two major appointments to its leadership team. Jason Campagna joins the company as President of R&D and Chief Medical Officer, succeeding Pierre Broqua and Michael Cooreman. Martine Zimmermann becomes Executive Vice President, Regulatory Affairs and Quality Assurance.

Jason Campagna brings significant expertise, having previously held key positions in the field of metabolic steatohepatitis associated with dysfunction (MASH). Martine Zimmermann, with experience at Ipsen and Alexion Pharma, will be instrumental in guiding the regulatory strategies for lanifibranor, a late-stage treatment for MASH.

These appointments aim to prepare Inventiva for the publication of the results of the NATiV3 study scheduled for 2026. Frédéric Cren, CEO of Inventiva, underlines the importance of these two recruitments in the company's growth and operational excellence approach.